Fol. Biol. 2008, 54, 157-161
https://doi.org/10.14712/fb2008054050157
Lack of B-RAF Mutations in Head and Neck Squamous Cell Carcinoma
References
1. , D. J., Li, Y., Adams, G.. L., Wagner, H. Jr., Kish, J. A., Ensley, J. F., Schuller, D. E., Forastiere, A. A. (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. 21, 92-98.
<https://doi.org/10.1200/JCO.2003.01.008>
2. , M., Gunduz, M., Nagatsuka, H., Gunduz, E., Cengiz, B., Fukushima, K., Beder, L. B., Demircan, K., Fujii, M., Yamanaka, N., Shimizu, K., Grenman, R., Nagai, N. (2008) Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci. 99, 1589-1594.
3. , J. E., Eaton, K. D., Martins, R. G. (2007) Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch. Dermatol. 143, 889-892.
<https://doi.org/10.1001/archderm.143.7.889>
4. , C. H., Ely, K., McGavran, L., Varella-Garcia, M., Parker, J., Parker, N., Jarrett, C., Carter, J., Murphy, B. A., Netterville, J., Burkey, B. B., Sinard, R., Cmelak, A., Levy, S., Yarbrough, W. G., Slebos, R. J., Hirsch, F. R. (2006) Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J. Clin. Oncol. 24, 4170-4176.
<https://doi.org/10.1200/JCO.2006.07.2587>
5. , E. E., Rosen, F., Stadler, W. M., Recant, W., Stenson, K., Huo, D., Vokes, E. E. (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 21, 1980-1987.
<https://doi.org/10.1200/JCO.2003.10.051>
6. , H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G.. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., Futreal, P. A. (2002) Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
<https://doi.org/10.1038/nature00766>
7. , C., Siu, L. L., Winquist, E., Agulnik, M., Pond, G.. R., Chin, S. F., Francis, P., Cheiken, R., Elting, J., McNabola, A., Wilkie, D., Petrenciuc, O., Chen, E. X. (2007) Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J. Clin. Oncol. 25, 3766-3773.
<https://doi.org/10.1200/JCO.2006.10.2871>
8. , V., Garnett, M., Mason, C., Marais, R. (2005) Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res. 65, 9719-9726.
<https://doi.org/10.1158/0008-5472.CAN-05-1683>
9. , Z., Smith, P. C., Zhang, L., Rubin, M. A., Dunn, R. L., Yao, Z., Keller, E. T. (2003) Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J. Natl. Cancer Inst. 95, 878-889.
<https://doi.org/10.1093/jnci/95.12.878>
10. , M. J., Marais, R. (2004) Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6, 313-319.
<https://doi.org/10.1016/j.ccr.2004.09.022>
11. , M., Nagatsuka, H., Demircan, K., Gunduz, E., Cengiz, B., Ouchida, M., Tsujigiwa, H., Yamachika, E., Fukushima, K., Beder, L., Hirohata, S., Ninomiya, Y., Nishizaki, K., Shimizu, K., Nagai, N. (2005) Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene 356, 109-117.
<https://doi.org/10.1016/j.gene.2005.02.014>
12. , M., Beder, L. B., Gunduz, E., Nagatsuka, H., Fukushima, K., Pehlivan, D., Cetin, E., Yamanaka, N., Nishizaki, K., Shimizu, K., Nagai, N. (2008) Downregulation of ING3 mRNA expression predicts poor prognosis in head and neck cancer. Cancer Sci. 99, 531-538.
<https://doi.org/10.1111/j.1349-7006.2007.00708.x>
13. , Y., Takeda, S., Ichii, S., Koizumi, K., Maruyama, M., Fujii, A., Ohta, H., Nakajima, T., Okuda, M., Baba, S. (1995) Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-specific amplification (MASA). Oncogene 10, 1441-1445.
14. , J., van den Broecke, C., Gijsen, S., Boots-Sprenger, S., Wesseling, P. (2007) RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol. 114, 121-133.
<https://doi.org/10.1007/s00401-007-0239-0>
15. , H., Spandidos, D. A., Jones, A. S., Vaughan, E. D., Field, J. K. (1995) Mutations, expression and genomic instability of the H-ras proto-oncogene in squamous cell carcinomas of the head and neck. Br. J. Cancer 72, 123-128.
<https://doi.org/10.1038/bjc.1995.287>
16. , A. M., A’Hern, R. P., D’Ambrosio, C., Tanay, M., Syrigos, K. N., Rogers, S. J., Box, C., Eccles, S. A., Nutting, C. M., Harrington, K. J. (2006) Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br. J. Cancer 94, 631-636.
<https://doi.org/10.1038/sj.bjc.6602999>
17. , R., Marshall, C. J. (1996) Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv. 27, 101-125.
18. R, L. M., Garcia-Cuellar, C. M., Herrera González, N. E., Suchil, B. L., Pérez-Cárdenas, E., Sácnchez-Pérez, Y., Suárez-Roa, M. L., Meneses, A. (2006) Mutational analysis of K-ras and Ras protein expression in larynx squamous cell carcinoma. J. Exp. Clin. Cancer Res. 25, 73-78.
19. , J. P., Lydiatt, W. (1995) Treatment of cancer of the head and neck. CA Cancer J. Clin. 45, 352-368.
<https://doi.org/10.3322/canjclin.45.6.352>
20. , A., Langhanki, L., Sommerer, F., Markwarth, A., Wittekind, C., Tannapfel, A. (2003) Mutations of the B-RAF gene in squamous cell carcinoma of the head and neck. Oncogene 22, 4757-4759.
<https://doi.org/10.1038/sj.onc.1206705>
21. , C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, D., Springer, C. J., Marais, R. (2004) V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64, 2338-2342.
<https://doi.org/10.1158/0008-5472.CAN-03-3433>
22. , X., Quiros, R. M., Gattuso, P., Ain, K. B., Prinz, R .A. (2003) High prevalence of B-RAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 63, 4561-4567.
23. , W. G., Shores, C., Witsell, D. L., Weissler, M. C., Fidler, M. E., Gilmer, T. M. (1994) Ras mutations and expression in head and neck squamous cell carcinomas. Laryngoscope 104, 1337-1347.
<https://doi.org/10.1288/00005537-199411000-00005>
24. , A., Staber, P. B., Delavar, A., Bodner, C., Hiden, K., Fischereder, K., Janakiraman, M., Linkesch, W., Auner, H. W., Emberger, W., Windpassinger, C., Schimek, M. G., Hoefler. G., Troppmair, J., Sill, H. (2006) Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res. 66, 3401-3408.
<https://doi.org/10.1158/0008-5472.CAN-05-0115>
